{"analyses":[{"groupDescription":"The comparison of the EFS between HLHR13 and historical control of HOD99 unfavorable risk 2 arm (UR2) was done by the two-sample log-rank test.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0008","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.951","upperLimit":"0.997","value":"0.974"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"description":"Event-free survival (EFS) is defined as the probability of survival between the date of study enrollment to the date of first event (relapsed or progressive disease, second malignancy, or death from any cause) or to last follow-up for patients without events. Under the proportional hazard model assumption, the two-sample log-rank test used to compare the EFS between HLHR13 and historical control of HOD99 unfavorable risk 2 arm (UR2).","dispersionType":"95% Confidence Interval","groups":[{"description":"Ann Arbor stage IIB, IIIB, IVA, or IVB participants receive:\n\n2 cycles of AEPA chemotherapy: (A) Brentuximab vedotin 1.2 mg/kg IV (intravenous) days 1, 8 and 15, (E) Etoposide 125 mg/m\\^2 IV days 1-5, (P) Prednisone 60 mg/m\\^2/day PO (orally) days 1-15, (A) Doxorubicin 40 mg/m\\^2 IV days 1 and 15), Followed by 4 cycles of CAPDac: (C) Cyclophosphamide 500 mg/m\\^2 IV days 1 and 8, (A) Brentuximab vedotin 1.2 mg/kg IV days 1 and 8, (P) Prednisone 40 mg/m\\^2/day PO days 1-15, (Dac) Dacarbazine 250 mg/m\\^2 IV days 1-3.).\n\nFilgrastim 5 mcg/kg subcutaneous (SC) as clinically indicated.\n\nFor those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy is given.","id":"OG000","title":"AEPA/CAPDac"}],"paramType":"NUMBER","populationDescription":"For HLHR13, all the evaluable participants that treated with AEPA/CAPDac; for HOD99 Unfavorable Risk 2 Arm (UR2), all the evaluable participants that treated with Stanford V + RT.","reportingStatus":"POSTED","timeFrame":"From start of therapy to 2 years after completion of therapy (up to 3 years after study enrollment)","title":"Comparison of the Event-free (EFS) Survival in High Risk HL Patients Treated With AEPA/CAPDac to the Historical Control HOD99 Unfavorable Risk 2 Arm (UR2).","type":"PRIMARY","unitOfMeasure":"probability"}